In a nutshell
This study examined the experiences which type 1 diabetics and their caregivers have with continuous glucose (sugar) monitoring.
Some background
A continuous glucose monitor (CGM) is a device worn by patients with type 1 diabetes (T1D). It allows patients to view their blood glucose levels in real-time (every few minutes). This device receives information about the blood glucose levels though a sensor placed underneath the skin. The device then displays the blood glucose levels a monitor.
A CGM may be combined with an insulin pump (a device that delivers insulin through a tube placed under the skin). In this case, the CGM monitors the blood glucose levels and sends the information to the insulin pump wirelessly. This allows the insulin pump to release insulin in a glucose-dependent manner. When blood glucose levels are low, an alarm can sound from the CGM and the CGM also instructs the insulin pump to stop releasing insulin.
Methods & findings
This study aimed to determine the opinions which T1D patients and their caregivers had in relation to CGM. This study involved 100 participants. Participants completed an online survey indicating their experiences with CGM.
87% of participants used CGM in combination with the insulin pump. 71% of participants used sensors at least 75% of the time. The experiences with CGM were primarily positive. Participants reported a reduction in HbA1c (average blood glucose levels over 3 months) and less variability in blood glucose levels. The CGM was valuable in detecting low blood glucose levels and also in reducing the frequency of low blood glucose levels.
Participants slept better when using a CGM. However, alarms may have sounded accidently if the patient lay on the CGM. Diet, exercise management and quality of life were improved. 52% reported positive psychological effects. 9% reported psychological effects such as worry over improving blood glucose levels.
Technical issues such as discomfort and pain when inserting the sensor were reported. CGM was considered very expensive and 66% of participants received funding from the National Health Service (UK).
The bottom line
This study concluded that a continuous glucose monitor is a valuable addition to patients with type 1 diabetes.
The fine print
Opinions were based on participants’ perceptions. Words such as ‘accuracy’ in relation to blood glucose levels were not defined. It may have also been useful to obtain opinions from healthcare professionals in addition.
What’s next?
Consult your physician regarding the benefits and availability of CGM.
Published By :
Diabetes Care
Date :
Dec 31, 2014
